The Ritedose Corporation
Ritedose is a leading pharmaceutical company specializing in sterile Blow-Fill-Seal (BFS) technology and generics manufacturing. Since 2012, they have delivered over 12 billion doses of critical medications with a focus on quality, safety, and innovation. Their mission is to help patients live their best lives through high-quality medications, supported by a culture of excellence, community engagement, and continuous innovation. They operate a world-class cGMP facility with extensive capacity and regulatory compliance, serving both early-stage drug developers and large pharmaceutical companies. Ritedose is committed to environmental sustainability, social responsibility, and maintaining the highest quality standards in their operations.
Industries
Nr. of Employees
large (251-1000)
The Ritedose Corporation
Columbia, South Carolina, United States, North America
Products
Generic formoterol fumarate inhalation solution (unit-dose)
Sterile unit-dose inhalation solution example (20 mcg/2 mL) provided as individually packaged single-dose vials for nebulized respiratory therapy.
Generic albuterol sulfate inhalation solution (unit-dose)
Sterile unit-dose inhalation solution examples (e.g., 2.5 mg/0.5 mL and other concentrations) for acute bronchodilator therapy in single-use vials.
Cromolyn sodium inhalation solution (unit-dose)
Sterile unit-dose inhalation solution example (e.g., 20 mg/2 mL) provided for nebulized respiratory therapy.
Arformoterol tartrate inhalation solution (unit-dose)
Sterile single-dose inhalation solution example (e.g., 15 mcg/2 mL) for maintenance respiratory therapy delivered via nebulization.
Sodium chloride inhalation solutions (unit-dose)
Sterile unit-dose saline inhalation solutions at multiple concentrations (e.g., 0.9%, 3%, 7%) for nebulized therapy and airway clearance.
Other generic inhalation solutions (levalbuterol, ipratropium, combinations)
Examples of additional sterile single-dose inhalation products such as levalbuterol, ipratropium bromide, and combination inhalation solutions provided in unit-dose formats.
Generic formoterol fumarate inhalation solution (unit-dose)
Sterile unit-dose inhalation solution example (20 mcg/2 mL) provided as individually packaged single-dose vials for nebulized respiratory therapy.
Generic albuterol sulfate inhalation solution (unit-dose)
Sterile unit-dose inhalation solution examples (e.g., 2.5 mg/0.5 mL and other concentrations) for acute bronchodilator therapy in single-use vials.
Cromolyn sodium inhalation solution (unit-dose)
Sterile unit-dose inhalation solution example (e.g., 20 mg/2 mL) provided for nebulized respiratory therapy.
Arformoterol tartrate inhalation solution (unit-dose)
Sterile single-dose inhalation solution example (e.g., 15 mcg/2 mL) for maintenance respiratory therapy delivered via nebulization.
Sodium chloride inhalation solutions (unit-dose)
Sterile unit-dose saline inhalation solutions at multiple concentrations (e.g., 0.9%, 3%, 7%) for nebulized therapy and airway clearance.
Other generic inhalation solutions (levalbuterol, ipratropium, combinations)
Examples of additional sterile single-dose inhalation products such as levalbuterol, ipratropium bromide, and combination inhalation solutions provided in unit-dose formats.
Services
Integrated contract development and manufacturing from early-stage clinical support through commercial manufacturing, including formulation development, validation, quality, and regulatory support.
High-speed automated primary and secondary packaging services for unit-dose and individually wrapped single-vial formats using multi-line packaging suites and robotic equipment.
On-site analytical chemistry and microbiology testing to support product release, stability assessment and quality investigations.
Validation planning and execution with lifecycle support to maintain validated state across commercial manufacturing operations.
Warehousing, distribution and logistics support from an on-site logistics facility to enable product distribution and supply-chain execution.
Integrated contract development and manufacturing from early-stage clinical support through commercial manufacturing, including formulation development, validation, quality, and regulatory support.
High-speed automated primary and secondary packaging services for unit-dose and individually wrapped single-vial formats using multi-line packaging suites and robotic equipment.
On-site analytical chemistry and microbiology testing to support product release, stability assessment and quality investigations.
Validation planning and execution with lifecycle support to maintain validated state across commercial manufacturing operations.
Warehousing, distribution and logistics support from an on-site logistics facility to enable product distribution and supply-chain execution.
Expertise Areas
- Aseptic unit-dose manufacturing
- Contract development and manufacturing (CDMO) services and scale-up
- Sterile inhalation and ophthalmic product manufacturing
- Sterile liquid formulation development
Key Technologies
- Blow–Fill–Seal aseptic filling
- Automated high-speed filling lines
- Robotic packaging and automated secondary packaging
- Medical-grade thermoplastic molding for single-dose containers (LDPE)
News & Updates
The company unveiled a new distribution and logistics facility in Columbia, SC, during a ribbon-cutting ceremony, enhancing their capacity to serve customers.
The company received FDA approval for a key inhalation solution addressing nationwide shortages.
Expansion of manufacturing capacity to support new COPD drug and other products.
Partnership to develop and deliver a novel COPD medication.
The company became the largest generic drug maker of its kind with a significant asset purchase.
The company unveiled a new distribution and logistics facility in Columbia, SC, during a ribbon-cutting ceremony, enhancing their capacity to serve customers.
The company received FDA approval for a key inhalation solution addressing nationwide shortages.
Expansion of manufacturing capacity to support new COPD drug and other products.
Partnership to develop and deliver a novel COPD medication.
The company became the largest generic drug maker of its kind with a significant asset purchase.